新世界發展(00017.HK)初創企業加速計劃Impact Kommons挑選15初創 六成為本地企業
新世界發展(00017.HK)公布,旗下全亞洲首個以聯合國可持續發展目標(UNSDG)為藍本的初創企業加速計劃Impact Kommons展開新一階段,挑選15間初創企業,以集團的網絡及資源協助入選其業務及方案商品化,並協助集團業務應用創新解決方案。
第二輪計劃有來自30個不同國家及地區的初創企業申請,最終15間憑藉其方案的獨特性脫穎而出,有達六成為本地企業,反映他們在可持續發展方案方面的潛力及商機。當中有入選初創的產品有效加強防疫抗疫的措施,並已獲集團旗下的物業採用。(el/k) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.